Mammographic density and breast cancer after ductal carcinoma in situ

Journal of the National Cancer Institute

Volumn 96, Issue 19, 2004, Pages 1467-1472

  Habel, Laurel A ^a   Dignam, James J ^b,c   Land, Stephanie R ^c,d   Salane, Martine ^e   Capra, Agela M ^a   Julian, Thomas B ^f  

^a DIVISION OF RESEARCH   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e MSW Consulting   (United States)

^f ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BODY MASS; BREAST CANCER; CANCER CLASSIFICATION; CANCER RISK; CARCINOMA IN SITU; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; HUMAN; IMAGE QUALITY; IMAGING SYSTEM; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REGRESSION ANALYSIS; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR VOLUME; VALIDATION PROCESS; AGED; BREAST; BREAST TUMOR; EPIDEMIOLOGY; INCIDENCE; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RADIOGRAPHY; RISK ASSESSMENT; RISK FACTOR; SINGLE BLIND PROCEDURE; TUMOR RECURRENCE; UNITED STATES;

ADULT; AGED; BREAST; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HUMANS; INCIDENCE; MAMMOGRAPHY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; RISK FACTORS; SINGLE-BLIND METHOD; UNITED STATES;

EID: 6944230092     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh260     Document Type: Article

References (42)

1. Saftlas AF, Szklo M. Mammographic parenchymal patterns and breast cancer risk. Epidemiol Rev 1987;9:146-74.
2. Oza AM, Boyd NF. Mammographic parenchymal patterns: a marker of breast cancer risk. Epidemiol Rev 1993;15:196-208.
3. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998;7:1133-44.
4. Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 1995;87:1622-9.
5. Kato I, Beinart C, Bleich A, Su S, Kim M, Toniolo PG. A nested case-control study of mammographic patterns, breast volume, and breast cancer (New York City, NY, United States). Cancer Causes Control 1995;6:431-8.
6. Byng JW, Boyd NF, Little L, Lockwood G, Fishell E, Jong RA, et al. Symmetry of projection in the quantitative analysis of mammographic images. Eur J Cancer Prev 1996; 5:319-27.
7. Stomper PC, Van Voorhis BJ, Ravnikar VA, Meyer JE. Mammographic changes associated with postmenopausal hormone replacement therapy: a longitudinal study. Radiology 1990;174:487-90.
8. Sterns EE, Zee B. Mammographic density changes in perimenopausal and postmenopausal women: is effect of hormone replacement therapy predictable? Breast Cancer Res Treat 2000;59:125-32.
9. Persson I, Thurfjell E, Holmberg L. Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density. J Clin Oncol 1997;15:3201-7.
10. Leung W, Goldberg F, Zee B, Sterns E. Mammographic density in women on postmenpausal hormone replacement therapy. Surgery 1997;122:669-74.
11. Laya MB, Gallagher JC, Schreiman JS, Larson EB, Watson P, Weinstein L. Effect of postmenopausal hormonal replacement therapy on mammographic density and parenchymal pattern. Radiology 1995;196:433-7.
12. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95:30-7.
13. Lundstrom E, Wilczek B, von Palffy Z, Soderqvist G, von Schoultz B. Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens. Climacteric 2001;4:42-8.
14. Ursin G, Pike MC, Spicer DV, Porrath SA, Reitherman RW. Can mammographic densities predict effects of tamoxifen on the breast? J Natl Cancer Inst 1996;88:128-9.
15. Chow CK, Venzon D, Jones EC, Premkumar A, O'Shaughnessy J, Zujewski J. Effect of tamoxifen on mammographic density. Cancer Epidemiol Biomarkers Prev 2000;9:917-21.
16. Brisson J, Brisson B, Cote G, Maunsell E, Berube S, Robert J. Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 2000;9:911-5.
17. Atkinson C, Warren R, Bingham SA, Day NE. Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiol Biomarkers Prev 1999;8:863-6.
18. Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 2000;160:953-8.
19. Fisher ER, Dignam J, Tan-Chiu E, Costantino J, Fisher B, Paik S, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer 1999;86:429-38.
20. Solin LJ, Fourquet A, Vicini FA, Haffty B, Taylor M, McCormick B, et al. Mammographically detected ductal carcinoma in situ of the breast treated with breast-conserving surgery and definitive breast irradiation: long-term outcome and prognostic significance of patient age and margin status. Int J Radiat Oncol Biol Phys 2001;50:991-1002.
21. Frykberg ER, Masood S, Copeland EM 3rd, Bland KI. Ductal carcinoma in situ of the breast. Surg Gynecol Obstet 1993;177:425-40.
22. Habel LA, Moe RE, Daling JR, Holte S, Rossing MA, Weiss NS. Risk of contralateral breast cancer among women with carcinoma in situ of the breast. Ann Surg 1997;225:69-75.
23. Habel LA, Daling JR, Newcomb PA, Self SG, Porter PL, Stanford JL, et al. Risk of recurrence after ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 1998;7:689-96.
24. Fisher ER, Sass R, Fisher B, Wickerham L, Paik SM. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6). I. Intraductal carcinoma (DCIS). Cancer 1986;57:197-208.
25. Silverstein MJ. Noninvasive breast cancer. The dilemma of the 1990s. Obstet Gynecol Clin North Am 1994;21:639-58.
26. Fisher B, Costantino J, Redmond C, Fisher E, Margolese R, Dimitrov N, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993;328:1581-6.
27. Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998;16:441-52.
28. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 2001;28:400-18.
29. Fisher ER, Costantino J, Fisher B, Palekar AS, Redmond C, Mamounas E. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). Cancer 1995;75:1310-9.
30. Wolfe JN, Safflas AF, Salane M. Mammographic parenchymal patterns and quantitative evaluation of mammographic densities: a case-control study. AJR Am J Roentgenol 1987;148:1087-92.
31. Kotz S, Johnson NL, editors. Encyclopedia of statistical sciences. Vol 4. Philadelphia (PA): John Wiley and Sons; 1983. p. 315-8, 414-6.
32. Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics 1978;34:541-54.
33. Kalbfleisch J, Prentice R. The statistical analysis of failure time data. New York (NY): John Wiley and Sons; 1980, p. 70-118.
34. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 1993;12:737-51.
35. Rothman KJ, Greenland S, eds. Modern epidemiology. 2nd ed. Philadelphia (PA): Lippincott-Raven; 1998, p. 256-9.
36. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003; 289:3243-53.
37. Byrne C. Studying mammographic density: implications for understanding breast cancer. J Natl Cancer Inst 1997;89:531-3.
38. Saftlas AF, Wolfe JN, Hoover RN, Brinton LA, Schairer C, Salane M, et al. Mammographic parenchymal patterns as indicators of breast cancer risk. Am J Epidemiol 1989; 129:518-26.
39. Saftlas AF, Hoover RN, Brinton LA, Szklo M, Olson DR, Salane M, et al. Mammographic densities and risk of breast cancer. Cancer 1991;67:2833-8.
40. Boyd NF, Greenberg C, Lockwood G, Little L, Martin L, Byng J, et al. Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast: results from a randomized trial. Canadian Diet and Breast Cancer Prevention Study Group. J Natl Cancer Inst 1997;89:488-96.
41. Atkinson C, Bingham SA. Mammographic breast density as a biomarker of effects of isoflavones on the female breast. Breast Cancer Res 2002;4:1-4.
42. Son HJ, Oh KK. Significance of follow-up mammography in estimating the effect of tamoxifen in breast cancer patients who have undergone surgery. AJR Am J Roentgenol 1999;173:905-9.